S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
NASDAQ:ITCI

Intra-Cellular Therapies (ITCI) Stock Forecast, Price & News

$52.09
-1.71 (-3.18%)
(As of 09/29/2023 08:53 PM ET)
Compare
Today's Range
$51.93
$54.35
50-Day Range
$52.09
$61.96
52-Week Range
$42.01
$67.05
Volume
614,500 shs
Average Volume
725,202 shs
Market Capitalization
$5.00 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$78.78

Intra-Cellular Therapies MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
51.2% Upside
$78.78 Price Target
Short Interest
Healthy
2.32% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.23
Upright™ Environmental Score
News Sentiment
1.35mentions of Intra-Cellular Therapies in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$6.36 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.08) to ($0.83) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.73 out of 5 stars

Medical Sector

91st out of 968 stocks

Pharmaceutical Preparations Industry

28th out of 448 stocks


ITCI stock logo

About Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, heart failure, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

ITCI Price History

ITCI Stock News Headlines

How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
How is This "Hidden Gem" Thriving in a Turbulent Market?
While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.
Intra-Cellular Therapies Q2 2023 Earnings Preview
ITCI Jul 2023 65.000 call
Analyst Expectations for Intra-Cellular Therapies's Future
See More Headlines
Receive ITCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter.

ITCI Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ITCI
Employees
561
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$78.78
High Stock Price Forecast
$98.00
Low Stock Price Forecast
$62.00
Forecasted Upside/Downside
+51.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
8 Analysts

Profitability

Net Income
$-256,260,000.00
Pretax Margin
-50.36%

Debt

Sales & Book Value

Annual Sales
$250.31 million
Book Value
$6.93 per share

Miscellaneous

Free Float
92,665,000
Market Cap
$5.00 billion
Optionable
Optionable
Beta
1.10
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Sharon Mates Ph.D. (Age 70)
    Co-Founder, Chairman, CEO & Pres
    Comp: $2.23M
  • Mr. Lawrence J. Hineline CPA (Age 67)
    CPA, Sr. VP of Fin., CFO, Treasurer & Assistant Sec.
    Comp: $820.53k
  • Mr. Michael I. Halstead J.D. (Age 50)
    Exec. VP, Gen. Counsel & Sec.
    Comp: $983.65k
  • Dr. Suresh K. Durgam M.D. (Age 54)
    Exec. VP & Chief Medical Officer
    Comp: $961.84k
  • Mr. Mark NeumannMr. Mark Neumann (Age 60)
    EVP & Chief Commercial Officer
    Comp: $998.36k
  • Dr. Robert E. Davis Ph.D. (Age 72)
    Sr. VP & Chief Scientific Officer
  • Mr. Juan Fernando Sanchez (Age 52)
    VP of Corp. Communications & Investor Relations
  • Ms. Karen Patruno Sheehy Esq. (Age 61)
    Sr. VP & Chief Compliance Officer
  • Dr. Michael Olchaskey
    Sr. VP & Head of Regulatory Affairs
  • Mr. John A. Bardi
    Sr. VP of Market Access, Policy & Gov. Affairs













ITCI Stock - Frequently Asked Questions

Should I buy or sell Intra-Cellular Therapies stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intra-Cellular Therapies in the last twelve months. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITCI shares.
View ITCI analyst ratings
or view top-rated stocks.

What is Intra-Cellular Therapies' stock price forecast for 2023?

8 brokers have issued 1 year price objectives for Intra-Cellular Therapies' shares. Their ITCI share price forecasts range from $62.00 to $98.00. On average, they predict the company's share price to reach $78.78 in the next twelve months. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for ITCI
or view top-rated stocks among Wall Street analysts.

How have ITCI shares performed in 2023?

Intra-Cellular Therapies' stock was trading at $52.92 at the beginning of 2023. Since then, ITCI shares have decreased by 1.6% and is now trading at $52.09.
View the best growth stocks for 2023 here
.

Are investors shorting Intra-Cellular Therapies?

Intra-Cellular Therapies saw a decrease in short interest during the month of September. As of September 15th, there was short interest totaling 2,230,000 shares, a decrease of 12.5% from the August 31st total of 2,550,000 shares. Based on an average daily trading volume, of 639,800 shares, the short-interest ratio is presently 3.5 days.
View Intra-Cellular Therapies' Short Interest
.

When is Intra-Cellular Therapies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our ITCI earnings forecast
.

How were Intra-Cellular Therapies' earnings last quarter?

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) issued its earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($0.45) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.17. The biopharmaceutical company earned $110.80 million during the quarter, compared to the consensus estimate of $106.45 million. Intra-Cellular Therapies had a negative trailing twelve-month return on equity of 28.63% and a negative net margin of 50.40%. Intra-Cellular Therapies's revenue for the quarter was up 99.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.92) EPS.

What other stocks do shareholders of Intra-Cellular Therapies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intra-Cellular Therapies investors own include Sorrento Therapeutics (SRNE), Amarin (AMRN), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Synergy Pharmaceuticals (SGYP), Myovant Sciences (MYOV), Novavax (NVAX), Pfizer (PFE), AbbVie (ABBV) and Clovis Oncology (CLVS).

What is Intra-Cellular Therapies' stock symbol?

Intra-Cellular Therapies trades on the NASDAQ under the ticker symbol "ITCI."

How do I buy shares of Intra-Cellular Therapies?

Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intra-Cellular Therapies' stock price today?

One share of ITCI stock can currently be purchased for approximately $52.09.

How much money does Intra-Cellular Therapies make?

Intra-Cellular Therapies (NASDAQ:ITCI) has a market capitalization of $5.00 billion and generates $250.31 million in revenue each year. The biopharmaceutical company earns $-256,260,000.00 in net income (profit) each year or ($1.93) on an earnings per share basis.

How many employees does Intra-Cellular Therapies have?

The company employs 561 workers across the globe.

How can I contact Intra-Cellular Therapies?

Intra-Cellular Therapies' mailing address is 430 EAST 29TH STREET, NEW YORK NY, 10016. The official website for the company is www.intracellulartherapies.com. The biopharmaceutical company can be reached via phone at (464) 440-9333, via email at ir@intracellulartherapies.com, or via fax at 646-440-9334.

This page (NASDAQ:ITCI) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -